Rechallenge pemetrexed-based chemotherapy provides an option for initially benefited patients with advanced lung adenocarcinoma

Detalles Bibliográficos
Autores principales: Wang, Jia-Ni, Qiao, Quan-Hui, Hu, Xing-Sheng, Liu, Yu-Tao, Wang, Zhi-Jie, Duan, Jian-Chun, Feng, Yu, Zhu, Hao-Hua
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2021
Materias:
Correspondence
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8440023/
https://www.ncbi.nlm.nih.gov/pubmed/34133351
http://dx.doi.org/10.1097/CM9.0000000000001511

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8440023/
https://www.ncbi.nlm.nih.gov/pubmed/34133351
http://dx.doi.org/10.1097/CM9.0000000000001511

Ejemplares similares